AOD-9604 vs MOTS-c: Metabolic Peptide Comparison
Written by NorthPeptide Research Team | Reviewed March 28, 2026
AOD-9604 and MOTS-c are both studied for metabolic effects, but they come from entirely different biological origins and target different metabolic pathways. AOD-9604 is a modified fragment of human growth hormone, while MOTS-c is encoded in the mitochondrial genome. Understanding their distinct mechanisms helps researchers choose the appropriate compound for their specific metabolic research questions.
Origins and Mechanism Differences
AOD-9604 (Anti-Obesity Drug 9604) is a modified peptide fragment corresponding to amino acids 177-191 of human growth hormone (hGH), with a tyrosine residue added at the N-terminus. It was developed by Monash University researchers who hypothesized that the lipolytic (fat-burning) activity of GH resided in a specific region of the molecule, separate from its growth-promoting effects. AOD-9604 stimulates lipolysis and inhibits lipogenesis without affecting IGF-1 levels or insulin sensitivity in the way full HGH does (PMID: 11713213).
MOTS-c is a 16-amino-acid peptide encoded within the 12S rRNA gene of mitochondrial DNA. Discovered in 2015 by researchers at USC, it activates the AMPK pathway through inhibition of the folate-methionine cycle. AMPK is a master regulator of cellular energy balance that promotes glucose uptake, fatty acid oxidation, and mitochondrial biogenesis (PMID: 25738459).
The key difference: AOD-9604 targets fat metabolism specifically (lipolysis), while MOTS-c affects whole-body energy regulation through AMPK, influencing glucose metabolism, fat oxidation, and mitochondrial function simultaneously.
Explore NorthPeptide's research-grade AOD-9604 — verified ≥98% purity with full COA documentation. View product details and COA →
Key Research Highlights
Fat Metabolism: AOD-9604 demonstrated lipolytic effects in obese animal models without the growth-promoting or diabetogenic side effects of HGH. It received GRAS (Generally Recognized as Safe) status from the FDA for use as a food ingredient (PMID: 11713213).
Exercise Mimicry: MOTS-c is described as an “exercise mimetic” because AMPK activation replicates many molecular effects of physical exercise — improved insulin sensitivity, enhanced glucose uptake, and increased mitochondrial biogenesis (PMID: 30575851).
Insulin Sensitivity: MOTS-c improved insulin sensitivity in high-fat diet models. AOD-9604 does not appear to significantly affect insulin sensitivity — it targets fat metabolism specifically.
Aging Connection: MOTS-c levels decline with age, suggesting a link between mitochondrial peptide signaling and age-related metabolic decline. AOD-9604 does not have this age-dependent characteristic.
Quick Reference
| Property | AOD-9604 | MOTS-c |
|---|---|---|
| Origin | HGH fragment (aa 177-191) | Mitochondrial DNA |
| Amino Acids | 16 | 16 |
| Primary Target | Fat metabolism (lipolysis) | AMPK / energy regulation |
| Glucose Effects | Minimal | Significant (insulin sensitizing) |
| Fat Effects | Direct lipolysis + anti-lipogenesis | Indirect via AMPK/fat oxidation |
| Age-Dependent | No | Yes (declines with age) |
| FDA Status | GRAS designation | Research compound |
Further Reading
For comprehensive analyses, see our AOD-9604 Research Guide | MOTS-c Research Guide
Also relevant: Metabolic Peptides Beyond GLP-1 →
Written by NorthPeptide Research Team
Ready to explore research-grade peptides?
Disclaimer: This article is for informational and educational purposes only. All peptides mentioned are intended for laboratory and research use only. Not for human consumption. NorthPeptide products are research chemicals and are not approved for medical use. Always consult applicable laws and regulations in your jurisdiction.